2015, Number 615
<< Back Next >>
Rev Med Cos Cen 2015; 72 (615)
Manejo de la fisura anal
Rivera AJA
Language: Spanish
References: 15
Page: 339-342
PDF size: 181.44 Kb.
ABSTRACT
The use of atypical antipsychotics
has significant improvements in
the treatment of schizophrenia.
Most patients do not experience
extrapyramidal side effects
of typical drugs, including
frequent irreversible tardive
dyskinesia and less sustained
elevation of prolactin. However,
serious adverse reactions
may also occur with atypical
antipsychotics without proper
treatment monitoring. While
the atypical antipsychotics have
modest efficacy advantages
over typical antipsychotics on
positive symptoms of psychosis,
they are more effective in
treating the negative symptoms.
Furthermore, it has recently
been proposed that this group
of drugs improve cell survival
and enhance neurogenesis.
REFERENCES
Azadeño, G. (2004). Efectos adversos asocuados al tratamiento con antipsicóticos atípicos. SESCAM.
Brunton, L. L., Chabner, B. A., & Knollmann, B. C. (2011). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12e. E.U.: McGraw- Hill.
Furtado, V., Srihari, V., & Kumar, A. (2012). Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Collaboration.
Garcia, M., & Medina , E. (2012). Treatment patterns un major depressive disorder after an inadequate response to first lin antidepressant tratment. BMC Psychiatry.
Hermes, E., & Sernyak, M. (2013). Use of second generation antipsychotic agents for sleep and sedation: a provider survey. Sleep, 36, 597-600.
Karandeep, N., & Agius, M. (2012). The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatria Danubia, 24, 95-99.
Keks, N. (2004). Are atypical antipsychotics advantegeous? , 146-9.
Leonard, C. (2013). Antipsychotics and the risks of sudden cardiac death and all cause of death: Cohort Studies in Medicaid and Dually-Eligible. 10, 1-9.
Lobo, A., & De la Mata, J. (2010). Nuevos Antipsicóticos. Salud Mental y Psiquiatría.
Mailman, R. B., & Murthy, V. (2010). Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Current Pharmaceutical Design, 488–501.
Medrano, J., Pacheco, L., & Zardoya, J. (2009). Uso No Autorizado de Psicofármacos . Real Decreto .
NICE. (2010). Schizophrenia. The NICE Guideline on Core Interventios in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary care. British Library.
Nicolas, A., & et al. (2010). Efficacy of atypical vs typical antipsychotics in the treatment of early psychosis: meta-analysis. BJP(196), 434-9.
Sumiyoshi, T. (2013). Antipsychotic treatments, focus on Lurasidone. Frontiers inf pharmacology, 1-7.
Tenjin, T., Miyamoto, S., & Ninomiya, Y. (2013). Profile of blonanserin for the treatment schizophrenia. Neuropsychiatric Disease and Treatment, 587–594
Full text